DL-(N)Pip-NHi-Pr | 85817-23-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DL-(N)Pip-NHi-Pr
• 英文别名: N-(Propan-2-yl)piperazine-2-carboxamide；N-propan-2-ylpiperazine-2-carboxamide
• CAS: 85817-23-8
• 化学式: C₈H₁₇N₃O
• 分子量: 171.242
• InChiKey: BQPORFHFPWJFIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  53.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  DL-(N)Pip-NHi-Pr 以 二氯甲烷 为溶剂， 反应 0.33h， 生成 Piv-DL-(N)Pip-NHi-Pr
  参考文献：
  名称：

  Hosten, N.; Antenuis, M.J.O, Bulletin des Societes Chimiques Belges, 1988, vol. 97, # 1, p. 48 - 50

  摘要：

  DOI：
• 作为产物：
  描述：

  Tetrahydro-oxazolo[3,4-a]pyrazine-1,3-dione 、 异丙胺 以 二氯甲烷 为溶剂， 生成 DL-(N)Pip-NHi-Pr
  参考文献：
  名称：

  Hosten, N.; Antenuis, M.J.O, Bulletin des Societes Chimiques Belges, 1988, vol. 97, # 1, p. 48 - 50

  摘要：

  DOI：

文献信息

• Amine Cationic Lipids and Uses Thereof
  申请人：Dicerna Pharmaceuticals, Inc.

  公开号：US20140371293A1

  公开（公告）日：2014-12-18

  The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent).

  本发明涉及脂质化合物及其用途。具体而言，这些化合物包括一类具有胺基团的阳离子脂质，例如氨基-胺或氨基-酰胺基团。这些脂质化合物可用于体内或体外传递一个或多个药物（例如，多聚阴离子荷载物或反义荷载物，如RNAi药物）。
• Novel N-aryl-piperazinealkanamides
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0068544A2

  公开（公告）日：1983-01-05

  Novel N-aryl-piperidineaikanamides, having particular substituents attached to one of the carbon atoms of the piperazine ring, which compounds can be used for ameliorating the blood perfusion of the muscular tissues of the heart and/or protecting the heart. partially or completely, from myocardial injury caused by more or less brief episodes of ischaemia, anoxia or hypoxia: processes of preparing such compounds and pharmaceutical compositions comprising such compounds as active ingredients.

  新型 N-芳基哌啶偕酰胺，其哌嗪环的一个碳原子上连接有特殊的取代基，该化合物可用于改善心脏肌肉组织的血液灌注和/或部分或完全保护心脏，使其免受或多或少短暂的缺血、缺氧或缺氧引起的心肌损伤：制备此类化合物的工艺和含有此类化合物作为活性成分的药物组合物。
• AMINE CATIONIC LIPIDS AND USES THEREOF
  申请人：Dicerna Pharmaceuticals, Inc.

  公开号：EP3960726A1

  公开（公告）日：2022-03-02

  The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents ( e.g. a polyanionic payload or an antisense payload, such as an RNAi agent).

  本发明涉及脂质化合物及其用途。特别是，这些化合物包括一类具有胺分子（如氨基酰胺分子）的阳离子脂质。这些脂质化合物可用于体内或体外递送一种或多种制剂（如多阴离子有效载荷或反义有效载荷，如 RNAi 制剂）。
• Amine cationic lipids and uses thereof
  申请人：Dicerna Pharmaceuticals, Inc.

  公开号：US11059807B2

  公开（公告）日：2021-07-13

  The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent).

  本发明涉及脂质化合物及其用途。特别是，这些化合物包括一类具有胺分子（如氨基胺或氨基酰胺分子）的阳离子脂质。这些脂质化合物可用于体内或体外递送一种或多种制剂（如多阴离子有效载荷或反义有效载荷，如 RNAi 制剂）。
• Process for formulating an anionic agent
  申请人：Dicerna Pharmaceuticals, Inc.

  公开号：US11351265B2

  公开（公告）日：2022-06-07

  Formulations comprising anionic agents such as nucleic acids within a lipid-containing particle methods of formulating a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for preparing a lipid-containing particle comprising an anionic agent such as a nucleic acid, methods for therapeutic delivery of an anionic agent to a patient in need thereof, where the anionic agent is formulated in a lipid-containing particle as described herein.

  包含阴离子剂（如含脂微粒中的核酸）的制剂 配制包含阴离子剂（如核酸）的含脂微粒的方法、制备包含阴离子剂（如核酸）的含脂微粒的方法、向有需要的患者治疗递送阴离子剂的方法，其中阴离子剂被配制在本文所述的含脂微粒中。